Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 17, 2021 07:30 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors

- Clinical activity observed in all three mesothelin-expressing tumor types treated - Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients - Overall...
July 20, 2021 06:45 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical Officer

CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with...
February 17, 2021 08:00 ET | Source: TCR2 Therapeutics

TCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
January 19, 2021 22:03 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies...
January 08, 2021 08:00 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones

- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21 - Identification of gavo-cel recommended Phase 2 dose and initiation of Phase 2 study expected in 2021 -...
December 21, 2020 08:00 ET | Source: TCR2 Therapeutics

TCR² Therapeutics to Present at J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
December 13, 2020 09:00 ET | Source: TCR2 Therapeutics

TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors

- TC-210 induced tumor regression in all of the first eight patients - Ovarian cancer patient achieved confirmed RECIST partial response (PR) - Overall response rate (ORR) 50% in patients...
December 11, 2020 16:05 ET | Source: TCR2 Therapeutics

TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors

CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients...
November 12, 2020 06:45 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

- Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20 - Additional clinical sites to include UCSF Medical Center and Princess Margaret Cancer Centre in the...
November 10, 2020 08:00 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing Capacity

- ElevateBio BaseCamp to support anticipated TC-210 Phase 2 clinical trial demand CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage...